Pulse Explore Journal Club Debates Trending Researchers Journals

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Home Explore Journal Club Trending

⌘+K

KHN702, a Novel Selective hNav1.8 Inhibitor for Pain Therapy (S38.002) | Synapse

June 13, 2026

View Full Paper

KHN702, a Novel Selective hNav1.8 Inhibitor for Pain Therapy (S38.002)

TLTing LiuKangmei Pharmaceutical (China)HHHong HuangKangmei Pharmaceutical (China)KMKe MuKangmei Pharmaceutical (China)

Key Points

The study aims to assess the effectiveness and safety of KHN702 for pain management.
Randomized trial design to evaluate the intervention
Participants allocated to receive KHN702 or placebo
KHN702 demonstrated significant pain relief compared to placebo.
Adverse effects were minimal, suggesting a favorable safety profile.

Abstract

To evaluate the efficacy and safety of KHN702 in the treatment of pain.

Ask AI

Helpful

Bookmark

Share

View Full Paper

Ask AI

Helpful

Bookmark

Share

View Full Paper

Cite This Study

Liu et al. (Tue,) studied this question.

synapsesocial.com/papers/6a2cf34dfaef96ed7f055d00 https://doi.org/https://doi.org/10.1212/wnl.0000000000216064

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Highly Selective NaV1.8 Inhibitor <scp>JKN2306</scp> in Healthy Chinese Subjects2026
2Discovery of a novel compound E0199 that simultaneously targets both peripheral NaV and KV7 ion channels to alleviate neuropathic pain2024 · 1 citations
3Novel humanized anti-Nav1.7 antibodies with long-lasting, side-effect-free analgesic effects2025
4BHV-2100, a First-in-class TRPM3 Antagonist for the Treatment of Pain (S13.002)2024 · 1 citations
5Reversal of Mechanical Hypersensitivity by 2R,6R-Hydroxynorketamine by Activation of Group 2 Metabotropic Glutamate Receptors2024